Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Oct 5 · below the Ichimoku cloud · RSI 62 · MACD above its signal
None of the 29 investors followed here reported a position in SGIOF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SGIOF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SGIOF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.0 | 27.7 | -13.4 | -4.6 | -1.1 | -0.4 | -7.2 | 1.1 | -7.1 | 9.5 | +18.0% | ||
| 2025 | 16.2 | 5.7 | 2.7 | -1.4 | 0.0 | 18.7 | -7.0 | 7.0 | 5.8 | -4.7 | -2.8 | -13.6 | +24.6% |
| 2024 | 0.0 | 10.4 | -2.7 | 0.0 | -6.1 | -16.2 | 0.7 | 18.1 | -1.9 | -15.6 | -3.0 | -1.6 | −20.7% |
| 2023 | -3.0 | -8.2 | 2.8 | -1.6 | -3.2 | -3.8 | 0.4 | 5.8 | -2.9 | 4.9 | 3.1 | -1.5 | −7.8% |
| 2022 | -16.9 | 11.5 | -6.1 | -9.2 | -5.6 | -5.9 | 2.9 | -6.2 | 0.0 | -4.7 | 10.0 | -1.0 | −29.7% |
| 2021 | -0.8 | -5.7 | 5.4 | -2.5 | -3.1 | 2.1 | 0.7 | 20.9 | 7.4 | -4.4 | 6.8 | 1.6 | +29.0% |
| 2020 | 0.3 | -17.0 | -5.7 | 18.8 | 0.1 | 9.2 | -5.0 | -7.5 | -3.4 | -13.1 | 15.2 | 2.4 | −11.3% |
| 2019 | 9.0 | 4.8 | -3.6 | -6.4 | -3.7 | 5.7 | -2.7 | -5.0 | 0.1 | 10.0 | -0.8 | 6.4 | +12.8% |
| 2018 | -5.6 | 0.1 | 1.8 | -2.3 | 9.1 | 3.3 | 12.8 | -2.1 | 2.7 | -14.8 | +2.4% |
No analyst coverage for this instrument.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.